
OSE Immunotherapeutics SA
PAR:OSE

OSE Immunotherapeutics SA
Other Current Liabilities
OSE Immunotherapeutics SA
Other Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Other Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
![]() |
OSE Immunotherapeutics SA
PAR:OSE
|
Other Current Liabilities
€2.9m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
N/A
|
|
![]() |
Valneva SE
PAR:VLA
|
Other Current Liabilities
€36.2m
|
CAGR 3-Years
-49%
|
CAGR 5-Years
30%
|
CAGR 10-Years
29%
|
|
![]() |
Nanobiotix SA
PAR:NANO
|
Other Current Liabilities
€33.1m
|
CAGR 3-Years
7%
|
CAGR 5-Years
42%
|
CAGR 10-Years
44%
|
|
G
|
Genfit SA
PAR:GNFT
|
Other Current Liabilities
€17.2m
|
CAGR 3-Years
147%
|
CAGR 5-Years
44%
|
CAGR 10-Years
12%
|
|
![]() |
Inventiva SA
PAR:IVA
|
Other Current Liabilities
€2.2m
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
N/A
|
|
![]() |
Eurobio Scientific SA
PAR:ALERS
|
Other Current Liabilities
€21.4m
|
CAGR 3-Years
17%
|
CAGR 5-Years
18%
|
CAGR 10-Years
24%
|
OSE Immunotherapeutics SA
Glance View
OSE Immunotherapeutics SA develops immunotherapy products for cancer and auto-immune disease. The company is headquartered in Nantes, Pays De La Loire and currently employs 61 full-time employees. The company went IPO on 2015-03-30. The company develops immunotherapies, directly or through partnerships, for the activation and regulation of the immune system in immuno-oncology and in autoimmune diseases. The firm's research and development in immunology is based on 3 platforms, such as T cell-based vaccines, Immuno-Oncology (myeloid targets) and Auto-Immunity & Inflammation. The company provides technological and scientific platforms: neoepitopes, agonist or antagonist monoclonal antibodies, ideally positioned to fight cancer and autoimmune diseases.

See Also
What is OSE Immunotherapeutics SA's Other Current Liabilities?
Other Current Liabilities
2.9m
EUR
Based on the financial report for Jun 30, 2024, OSE Immunotherapeutics SA's Other Current Liabilities amounts to 2.9m EUR.
What is OSE Immunotherapeutics SA's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 5Y
-25%
Over the last year, the Other Current Liabilities growth was 1 627%. The average annual Other Current Liabilities growth rates for OSE Immunotherapeutics SA have been -8% over the past three years , -25% over the past five years .